Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2), a FemTech medical device company, has been granted US patent No. 12654025B2 for its innovative technology. The patent represents a significant milestone in the company's commitment to advancing next-generation solutions for women's health.
Patent Details and Company Vision
The newly granted patent protects Zero Candida's unique technology, which integrates artificial intelligence, precision blue light therapy, and targeted drug delivery into a tampon-like device called ZC-001. According to the company, the device is designed to treat Vulvovaginal Candidiasis (VVC), a condition affecting approximately 75% of women worldwide. Recurrent cases—defined as four or more episodes per year—are increasingly resistant to existing drug treatments.
Zero Candida views the device as both a therapeutic and gynecological tool for the next century. The company states that the device will develop AI capabilities to treat vaginal fungus infections, detect new diseases, report directly to doctors, and order medication from pharmacies.
ZC-001: Smart Therapeutic Device
ZC-001 is described as a SMART, AI-enabled therapeutic device that combines precision blue light therapy, targeted drug delivery, and wireless diagnostics for personalized at-home treatment of VVC. The device aims to improve outcomes in recurrent and drug-resistant infections while reducing the need for repeated in-clinic visits. Its underlying technology may support future applications across other areas of women's health.
Market Potential and Company Background
Zero Candida is a publicly traded FemTech company focused on addressing unmet needs in women's health. The VVC treatment market is projected to exceed US $2 billion by 2030. The company is combining hybrid medicine and technology-based diagnostics to improve access for underserved populations and modernize gynecology.
Forward-looking statements in the press release caution that actual results may differ materially from those anticipated. The company does not undertake to update forward-looking statements except as required by law. Neither the TSXV nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of the release.
